化合物PQR-530 T16567

Product Introduction
Bioactivity


英文名: PQR530

描述: PQR530 是一具有口服活性，种 ATP 竞争性的，可透过血脑屏障的 PI3K/mTORC1/2双重抑制剂，对于 PI3Kα 和 mTOR (分别为 0.84 和 0.33 nM) 的Kd 为亚摩尔。它具有抗肿瘤作用。

体外活性: PQR-530 inhibits all PI3K isoforms and mTOR complexes C1/2 potently and selectively. PQR-530 inhibits protein kinase B (PKB, pSer473) and ribosomal protein S6 (pS6, pSer235/236) phosphorylation (IC50: 0.07 μM in A2058 melanoma cells). PQR-530 displays inhibitory activity against the growth of 44 cancer cell lines (mean GI50: 426 nM)[1].

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 25 mg/mL (61.36 mM)


关键字: Inhibitor | PQR530 | Phosphoinositide 3-kinase | PQR 530 | PI3K | inhibit | Mammalian target of Rapamycin | mTOR

相关产品: hSMG-1 inhibitor 11j | Deguelin | WYE-354 | PI3K-IN-47 | ETP-46321 | Euscaphic acid | Copanlisib dihydrochloride | DS-7423 | Communic acid | PI3K-IN-38

相关库: PI3K-AKT-mTOR Compound Library | Anti-Liver Cancer Compound Library | Anti-Breast Cancer Compound Library | Oxidation-Reduction Compound Library | Inhibitor Library | Kinase Inhibitor Library | Anti-Diabetic Compound Library | Anti-Colorectal Cancer Compound Library | Anti-Cancer Active Compound Library | Reprogramming Compound Library

化合物PQR-530 T16567信息由TargetMol中国为您提供，如您想了解更多关于化合物PQR-530 T16567报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途